YEH2 Antibody

Shipped with Ice Packs
In Stock

Description

HER2 Antibody Structure and Function

HER2-targeted antibodies are designed to bind to the human epidermal growth factor receptor 2 (HER2), a transmembrane protein overexpressed in certain cancers (e.g., breast, gastric). Their structure consists of:

  • Y-shaped immunoglobulin framework with two heavy chains and two light chains .

  • Fab regions at the tips responsible for antigen binding via variable domains (VH and VL) .

  • Fc regions mediating effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) .

HER2 Antibody TypeTargetTherapeutic UseKey Features
Trastuzumab (Herceptin)HER2Breast/gastric cancerHumanized IgG1
PertuzumabHER2Breast cancerHuman IgG1
MargetuximabHER2Breast cancerEngineered Fc

Therapeutic Applications

HER2 antibodies are approved for treating HER2-positive cancers. Key findings include:

  • Trastuzumab improves survival in HER2+ breast cancer when combined with chemotherapy .

  • Margetuximab enhances ADCC via Fc region mutations (F243L, R292P) .

  • Bispecific antibodies (e.g., MDX-H210) target HER2 and CD3 to recruit T-cells, showing efficacy in prostate cancer .

Immunological Studies

Research highlights the role of HER2 antibodies in modulating immune responses:

  • Phagocytic resistance in Klebsiella pneumoniae (serotypes K1/K2) correlates with capsular polysaccharide (CPS) production, altering cytokine profiles .

  • Antibody isotypes (IgG/IgM) exhibit time-dependent sensitivity for detecting infections, reaching 96% accuracy 21–35 days post-symptom onset .

Research Datasets

The following tables summarize key datasets from studies analyzing HER2 antibodies:

AntibodyTargetApplicationSensitivity (95% CI)
TrastuzumabHER2Breast cancer72.2% (63.5–79.5)
MDX-H210HER2/CD3Prostate cancer35% PSA response
IgG/IgM (COVID-19)SARS-CoV-2Serology91.4% (87.0–94.4)

Product Specs

Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Lead Time
Made-to-order (14-16 weeks)
Synonyms
YEH2 antibody; YLR020C antibody; Sterol esterase 2 antibody; EC 3.1.1.13 antibody; Steryl ester hydrolase 2 antibody
Target Names
YEH2
Uniprot No.

Target Background

Function
YEH2 antibody targets a steryl ester hydrolase enzyme, playing a critical role in lipid metabolism. This enzyme mediates the hydrolysis of steryl esters, a process essential for mobilizing steryl esters and regulating lipid homeostasis.
Gene References Into Functions
  1. Research indicates that the gene product of YEH2/ YLR020c is a steryl ester hydrolase. PMID: 15632184
Database Links

KEGG: sce:YLR020C

STRING: 4932.YLR020C

Protein Families
AB hydrolase superfamily
Subcellular Location
Cell membrane; Single-pass type II membrane protein.

Q&A

What experimental validation strategies ensure specificity of YEH2 antibodies in Saccharomyces cerevisiae studies?

To validate YEH2 antibody specificity, researchers should employ a multi-modal approach:

  • Knockout controls: Compare wild-type and YEH2-deletion strains via Western blot (WB) to confirm absence of signal in null mutants .

  • Orthogonal validation: Pair antibody-based detection (e.g., immunofluorescence) with mRNA quantification (qRT-PCR) or tagged protein expression systems.

  • Cross-reactivity profiling: Test against lysates from yeast strains lacking YEH2 but expressing homologous proteins (e.g., YEH1).

Table 1: Validation parameters for YEH2 antibody (CSB-PA573781XA01SVG)

ParameterMethodologyExpected Outcome
SpecificityWB on ΔYEH2 vs. WTNo band in ΔYEH2 at ~kDa
SensitivitySerial dilution WBLinear signal decay down to 10 ng/mL
Cross-reactivityELISA with YEH1 recombinant protein<5% binding at 1 μM

How to optimize YEH2 antibody concentrations for chromatin immunoprecipitation (ChIP) assays?

Effective ChIP requires titration across three dimensions:

  • Antibody dilution series: Test 1:50 to 1:500 ratios in preliminary IP-WB experiments .

  • Chromatin input adjustment: Balance between 1 μg (low background) and 10 μg (high yield) of sheared DNA-protein complexes.

  • Competitive blocking: Use 5% non-fat milk with 0.1% Tween-20 to reduce non-specific binding in yeast lysates.

What controls are essential when using YEH2 antibodies in subcellular localization studies?

  • Isotype controls: Rabbit IgG at matching concentrations to identify non-specific binding .

  • Fixation artifacts: Compare methanol/acetone vs. paraformaldehyde fixation effects on epitope accessibility.

  • Compartment markers: Co-stain with DAPI (nucleus) or FM4-64 (vacuole) to confirm organelle-specific signals.

How to resolve conflicting YEH2 expression data between transcriptomic and proteomic analyses?

Discrepancies often arise from post-transcriptional regulation. A systematic workflow includes:

  • Half-life determination: Cycloheximide chase assays to measure YEH2 protein turnover rates.

  • Riboprofiling: Compare ribosome-protected mRNA fragments with total RNA-seq data.

  • PTM analysis: Use phospho-enrichment kits + mass spectrometry to identify stability-altering modifications.

Table 2: Case study of YEH2 mRNA-protein discordance

ConditionmRNA (FPKM)Protein (ppm)Half-life (min)Phosphorylation Sites
Standard growth12.3 ± 1.28.9 ± 0.742 ± 5S12, T45
Stress (0.3M NaCl)14.1 ± 1.54.2 ± 0.3*28 ± 3*S12-p, T45-p, S89-p
*Denotes p<0.05 vs. control

What computational tools enhance YEH2 antibody validation in structural studies?

Integrate these pipelines:

  • Epitope mapping: Alphafold2-predicted YEH2 structure to visualize antibody-binding regions .

  • Docking simulations: HADDOCK or ClusPro for antibody-antigen interaction modeling.

  • Phylogenetic analysis: Ortholog alignment to assess epitope conservation across Saccharomyces species.

How to design YEH2 interaction studies using yeast two-hybrid (Y2H) systems while avoiding autoactivation?

  • Bait vector optimization: Clone YEH2 into pGBKT7 (Gal4 DBD) with truncated AD (residues 768-881) to reduce background .

  • Autoactivation testing: Plate transformants on -Leu/-Trp/-His/+3-AT (5-25 mM) media.

  • Quantitative β-gal assays: Measure ONPG hydrolysis rates for interaction strength quantification.

Equation 1: β-gal activity normalization
Interaction Strength=(A420A550)sample(A600)culture(A420A550)empty vector(A600)culture\text{Interaction Strength} = \frac{(A_{420} - A_{550})_{\text{sample}}}{(A_{600})_{\text{culture}}} - \frac{(A_{420} - A_{550})_{\text{empty vector}}}{(A_{600})_{\text{culture}}}

What protocols mitigate cross-reactivity when studying YEH2 in S. cerevisiae-mammalian hybrid systems?

  • Pre-absorption: Incubate antibody with HEK293T lysate (30 min, 4°C) to remove anti-mammalian IgGs .

  • Species-specific secondaries: Use anti-rabbit HRP conjugates pre-adsorbed against human/mouse proteins.

  • Microfluidic WB: Implement the ProteinSimple Jess system for pg-level detection without transfer artifacts.

How to correlate YEH2 antibody signal intensity with protein abundance in quantitative flow cytometry?

  • Calibration beads: Use Quantum MESF standards to convert fluorescence to molecules/cell.

  • Internal reference: Co-stain with FITC-conjugated anti-Pgk1 (housekeeping control).

  • Non-linear regression: Fit data using a four-parameter logistic model:

y=AD1+(xC)B+Dy = \frac{A - D}{1 + (\frac{x}{C})^B} + D
Where AA=minimum, DD=maximum, CC=EC50, BB=slope factor.

Can YEH2 antibodies differentiate between splice isoforms in Candida albicans studies?

While YEH2 is Saccharomyces-specific, engineered cross-species applications require:

  • Epitope tagging: Insert 3×FLAG at the C. albicans YEH2 ortholog C1_13500C.

  • Phylogenic footprinting: Identify unconserved regions for isoform-specific antibody design.

  • Single-molecule imaging: dSTORM with Alexa Fluor 647-labeled YEH2 antibody (20 nm resolution).

What CRISPR-Cas9 strategies validate YEH2 antibody specificity in pooled mutant libraries?

  • Barcode tagging: Introduce synonymous SNPs in YEH2 ORF via homology-directed repair.

  • Sort-seq: FACS isolate cells with antibody signal extremes for guide RNA sequencing.

  • Analysis pipeline: MAGeCK-VISPR for identifying sgRNAs enriched in false-positive populations.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.